Phosphoproteomic profiling of human myocardial tissues distinguishes ischemic from non-ischemic end stage heart failure.

dc.contributor.author

Schechter, Matthew A

dc.contributor.author

Hsieh, Michael KH

dc.contributor.author

Njoroge, Linda W

dc.contributor.author

Thompson, J Will

dc.contributor.author

Soderblom, Erik J

dc.contributor.author

Feger, Bryan J

dc.contributor.author

Troupes, Constantine D

dc.contributor.author

Hershberger, Kathleen A

dc.contributor.author

Ilkayeva, Olga R

dc.contributor.author

Nagel, Whitney L

dc.contributor.author

Landinez, Gina P

dc.contributor.author

Shah, Kishan M

dc.contributor.author

Burns, Virginia A

dc.contributor.author

Santacruz, Lucia

dc.contributor.author

Hirschey, Matthew D

dc.contributor.author

Foster, Matthew W

dc.contributor.author

Milano, Carmelo A

dc.contributor.author

Moseley, M Arthur

dc.contributor.author

Piacentino, Valentino

dc.contributor.author

Bowles, Dawn E

dc.contributor.editor

Hosoda, Toru

dc.coverage.spatial

United States

dc.date.accessioned

2017-04-04T17:15:58Z

dc.date.available

2017-04-04T17:15:58Z

dc.date.issued

2014

dc.description.abstract

The molecular differences between ischemic (IF) and non-ischemic (NIF) heart failure are poorly defined. A better understanding of the molecular differences between these two heart failure etiologies may lead to the development of more effective heart failure therapeutics. In this study extensive proteomic and phosphoproteomic profiles of myocardial tissue from patients diagnosed with IF or NIF were assembled and compared. Proteins extracted from left ventricular sections were proteolyzed and phosphopeptides were enriched using titanium dioxide resin. Gel- and label-free nanoscale capillary liquid chromatography coupled to high resolution accuracy mass tandem mass spectrometry allowed for the quantification of 4,436 peptides (corresponding to 450 proteins) and 823 phosphopeptides (corresponding to 400 proteins) from the unenriched and phospho-enriched fractions, respectively. Protein abundance did not distinguish NIF from IF. In contrast, 37 peptides (corresponding to 26 proteins) exhibited a ≥ 2-fold alteration in phosphorylation state (p<0.05) when comparing IF and NIF. The degree of protein phosphorylation at these 37 sites was specifically dependent upon the heart failure etiology examined. Proteins exhibiting phosphorylation alterations were grouped into functional categories: transcriptional activation/RNA processing; cytoskeleton structure/function; molecular chaperones; cell adhesion/signaling; apoptosis; and energetic/metabolism. Phosphoproteomic analysis demonstrated profound post-translational differences in proteins that are involved in multiple cellular processes between different heart failure phenotypes. Understanding the roles these phosphorylation alterations play in the development of NIF and IF has the potential to generate etiology-specific heart failure therapeutics, which could be more effective than current therapeutics in addressing the growing concern of heart failure.

dc.identifier

https://www.ncbi.nlm.nih.gov/pubmed/25117565

dc.identifier

PONE-D-14-19226

dc.identifier.eissn

1932-6203

dc.identifier.uri

https://hdl.handle.net/10161/13939

dc.language

eng

dc.publisher

Public Library of Science (PLoS)

dc.relation.ispartof

PLoS One

dc.relation.isversionof

10.1371/journal.pone.0104157

dc.subject

Aged

dc.subject

Cluster Analysis

dc.subject

Computational Biology

dc.subject

Diagnosis, Differential

dc.subject

Gene Expression Profiling

dc.subject

Heart Failure

dc.subject

Heart Ventricles

dc.subject

Humans

dc.subject

Male

dc.subject

Metabolome

dc.subject

Metabolomics

dc.subject

Middle Aged

dc.subject

Myocardial Ischemia

dc.subject

Myocardium

dc.subject

Phosphopeptides

dc.subject

Phosphoproteins

dc.subject

Protein Interaction Mapping

dc.subject

Protein Interaction Maps

dc.subject

Proteome

dc.subject

Proteomics

dc.subject

Reproducibility of Results

dc.title

Phosphoproteomic profiling of human myocardial tissues distinguishes ischemic from non-ischemic end stage heart failure.

dc.type

Journal article

duke.contributor.orcid

Feger, Bryan J|0000-0002-5140-4414

duke.contributor.orcid

Ilkayeva, Olga R|0000-0002-9779-0883

duke.contributor.orcid

Hirschey, Matthew D|0000-0003-4541-5376

duke.contributor.orcid

Foster, Matthew W|0000-0003-0212-2346

duke.contributor.orcid

Bowles, Dawn E|0000-0002-2781-1300

pubs.author-url

https://www.ncbi.nlm.nih.gov/pubmed/25117565

pubs.begin-page

e104157

pubs.issue

8

pubs.organisational-group

Basic Science Departments

pubs.organisational-group

Cell Biology

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Duke

pubs.organisational-group

Duke Cancer Institute

pubs.organisational-group

Duke Molecular Physiology Institute

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Medicine

pubs.organisational-group

Medicine, Cardiology

pubs.organisational-group

Medicine, Endocrinology, Metabolism, and Nutrition

pubs.organisational-group

Medicine, Pulmonary, Allergy, and Critical Care Medicine

pubs.organisational-group

Pharmacology & Cancer Biology

pubs.organisational-group

Sarah Stedman Nutrition & Metabolism Center

pubs.organisational-group

School of Medicine

pubs.organisational-group

Staff

pubs.organisational-group

Surgery

pubs.organisational-group

Surgery, Cardiovascular and Thoracic Surgery

pubs.organisational-group

Surgery, Surgical Sciences

pubs.publication-status

Published online

pubs.volume

9

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Phosphoproteomic profiling of human myocardial tissues distinguishes ischemic from non-ischemic end stage heart failure.pdf
Size:
1.88 MB
Format:
Adobe Portable Document Format